Table 4 Clinical results, complications, and follow-up
Ref. | Complications | Stable ocular surface, n/N (%) | VA improvement, n/N (%) | Improvement in at least 2 lines of BCVA, n/N (%) | Mean follow-up ± SD (range) in months |
|---|---|---|---|---|---|
[13] | Corneal epithelial defect/bacterial infection × 2 | 6/6 (100) | 6/6 (100) | 6/6 (100) | 13.8 ± 2.9 (11–17) |
[14] | No complications | 4/4 (100) | 4/4 (100) | 4/4 (100) | 14 (13–15) |
[15] | Epithelial defect × 5 | 13/15 (86.7) | 12/15 (80) | 12/15 (80) | 20 (3–34) |
[16] | No complication | 2/2 (100) | 2/2 (100) | 2/2 (100) | 22.5 (19–26) |
[17] | Bacterial infection × 1, epithelial defects × 4 | 10/10 (100) | 9/10 (90) | 9/10 (90) | 12.6 ± 3.9 (8–19) |
[18] | Bacterial infection × 1, recurrent small epithelial defects × NA | 4/6 (66.7) | NA | NA | NA |
[19] | Increased intraocular pressure × 1 | 4/4 (100) | 4/4 (100) | 4/4 (100) | 16 (6–24) |
[20] | NA | NA | 4/4 (100) | 4/4 (100) | 31 (27–35) |
[21] | Microperforation × 1, PED × 1 | NA | 5/5 (100) | 5/5 (100) | 29.6 ± 3.6 (26–34) |
[22] | Corneal graft rejection × 2 | 5/10 (50) | 5/10 (50) | 3/10 (30) | 18.6 (1–38) |
[23] | PED × 19, stromal melting or perforation × 8, corneal infection 3 (bacterial infection × 2, recurrence of epithelial herpes simplex × 1), glaucoma × 8 (3 were new), evisceration × 2 | 23/40 (57.5) | 23,6/40 (59) | NA d | 25.5 (6–54.9) |
[24] | PED × 7, bacterial infection × 1, ocular hypertension × 3 | NA | 18/19 (95) | 15/19 (79) | 55 ± 17 (36–90) |
[25] | Recurrence of entropion × 1, epithelial defect × 1, Symblepharon 1 | 2/3 (66.7)a | NA | NA | 30 (11–50) |
[26] | Symblepharon × 1, Pain and graft complication × 1, inflammation × 2, corneal graft rejection × 1, keratitis × 1, increased IOP × 1, corneal perforation × 1, Meibomian cyst × 1, pain and corneal recurrence × 1 | NAb | 17/23 (73.91) c | 16/23 (69.5)c | 11.83 (NA) |
[27] | Small epithelial defect × 1, PED × 10, ocular hypertension × 3 | Substrate-free: 10/16 (62.5) AM: 6/16 (37.5) Total: 16/32 (50) | Substrate-free: 11/16 (68.8) AM: 7/16 (43.8) Total: 18/32 (56.3) | Substrate-free: 11/16 (68.8) AM: 7/16 (43.8) Total: 18/32 (56.3) | 25.26 ± 10.8 (14.45–36.08) (substrate-free)e 33.73 ± 17 (16,68–50.79) (AM) |
[28] | Glaucoma × 1 | 6/6 (100) | 6/6 (100) | 6/6 (100) | 36.7 + 17 (16–56) |
[29] | Hepatic dysfunction × 1, drug-induced allergy × 1, PED × 16, corneal stromal melting × 2, keratitis × 1, endophthalmitis × 1, infiltration × 3, increased IOP × 4 | NA | 26/46 (56.52) | 25/46 (54.3) | 28.7 (6.2–85.6) |
[30] | Epithelial defect × 3, increased IOP × 2, bacterial infection × 1 | 10/10 (100) | 2/10 (20) | 2/10 (20) | 22.79 (5.6–39.7) |
[31] | Central corneal epithelial defect × 1 | 2/2 (100) | 2/2 (100) | 2/2 (100) | 31 (21–41) |
[32] | Stromal scarring or conjunctival vascularization or stromal vascularization × 3, epithelial defect × 4 | 13/17 (76.5) | 15/17 (88.2) | 15/17 (88.2) | 16 (12–18) |
[33] | PED × 1, perforation × 1 | 15/20 (75) | 14/20 (70)d | NA | 31.9 ± 12.1 (8–50) |
[34] | Epithelial defect × 3, PED × 1, bacterial keratitis × 1, increased IOP × 2, endothelial graft rejection × 4 | 13/14 (92.9) | 14/14 (100) | 14/14 (100) | 28.2 ± 8.0 (14–40) |
[35] | Central epithelial defect × 1, symblepharon × 1, PED × 1, primary failure × 1, recurrence of an epithelial defect × 2 | 6/8 (75) | 5/8 (62.5) | 5/8 (62.5) | 9.96 ± 4.7 (2.07–15,8)f |
[36] | Epithelial defect × 3, PED × 9, increased IOP × 2, stroma melting × 5 | 18/34 (52.94) | 14/34 (41.17) | 5/34 (14.7) | 16.1 ± 5.8 (range NA) |
Total | 172/243 (70.78) | 225.6/331 (68.15) | 172/271 (63.46) |